Physician profile
Eric T Gross
NPI 1336135516
$25,969.19
in general payments reported to CMS, 2019-2025
52 companies · $626 in 2025
The $626 reported for 2025 was more than what 78% of Radiation Oncology providers received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $19K · 2020: $3,684 · 2021: $330 · 2022: $815 · 2023: $797 · 2024: $761 · 2025: $626.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,141 · Education: $43.25.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,140.57 |
| Education | $43.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $17,900.91 | 2019-2023 | Spaceoar Vue System - 10ml |
| Augmenix, INC. | $4,500.00 | 2019 | |
| Janssen Biotech, INC. | $326.68 | 2020-2024 | Rybrevant |
| Merck Sharp & Dohme LLC | $299.45 | 2021-2025 | Keytruda, Lynparza, Welireg |
| Novartis Pharmaceuticals Corporation | $201.24 | 2020-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $184.88 | 2019-2023 | |
| Abbvie INC. | $171.64 | 2021-2025 | |
| Emd Serono, INC. | $164.52 | 2022-2025 | Bavencio |
| Teleflex LLC | $146.88 | 2025 | Barrigel |
| Astrazeneca Pharmaceuticals LP | $137.90 | 2024-2025 | Enhertu, Imfinzi |
| Takeda Pharmaceuticals U.S.A., INC. | $129.03 | 2022-2024 | Ninlaro, Fruzaqla, Alunbrig |
| Pfizer INC. | $123.71 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $122.91 | 2023 | Libtayo |
| Daiichi Sankyo INC. | $96.41 | 2021-2023 | Enhertu |
| Visionrt, INC. | $95.46 | 2024 |
Show all 52 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ipsen Biopharmaceuticals, INC | $92.50 | 2020-2023 | Tazverik |
| Adc Therapeutics America, INC. | $90.43 | 2025 | |
| Aveo Pharmaceuticals, INC. | $84.89 | 2022-2025 | Fotivda |
| Seagen INC. | $70.34 | 2020-2023 | Adcetris, Padcev |
| Amgen INC. | $68.92 | 2021-2023 | Kyprolis |
| Myovant Sciences INC. | $64.06 | 2021-2022 | |
| Intuitive Surgical, INC. | $62.36 | 2022 | |
| Incyte Corporation | $59.43 | 2022-2025 | Jakafi, Zynyz, Monjuvi |
| Eisai INC. | $55.43 | 2022-2025 | |
| Jazz Pharmaceuticals INC. | $45.80 | 2020-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $44.33 | 2021-2024 | Gilotrif |
| Davol INC. | $41.22 | 2024 | Progel Applicator Spray Tips |
| Genzyme Corporation | $39.74 | 2020-2022 | |
| Cti Biopharma Corp. | $38.73 | 2023 | Vonjo |
| Ferring Pharmaceuticals INC. | $32.58 | 2019 | |
| Exelixis INC. | $32.40 | 2022 | |
| Lilly USA, LLC | $31.05 | 2021-2024 | Verzenio, Jaypirca |
| Dendreon Pharmaceuticals LLC | $29.71 | 2019 | |
| Sun Pharmaceutical Industries INC. | $27.97 | 2023 | Odomzo, Yonsa |
| Karyopharm Therapeutics INC. | $26.37 | 2023-2024 | Xpovio |
| Puma Biotechnology, INC. | $25.53 | 2024 | |
| Blueprint Medicines Corporation | $23.52 | 2024 | Ayvakit |
| Astellas Pharma US INC | $22.49 | 2019 | |
| Sobi, INC | $21.92 | 2022 | |
| Gilead Sciences, INC. | $21.89 | 2022 | |
| Beigene USA, INC. | $21.49 | 2024 | Brukinsa |
| Coherus Oncology, INC. | $21.10 | 2021 | |
| Tersera Therapeutics LLC | $20.09 | 2024 | Zoladex |
| Kite Pharma, INC. | $19.82 | 2025 | Yescarta |
| Agios Pharmaceuticals, INC. | $18.40 | 2025 | Pyrukynd |
| Sirtex Medical INC | $17.65 | 2022 | |
| G1 Therapeutics, INC. | $17.30 | 2022 | |
| Stemline Therapeutics INC. | $17.25 | 2023 | Orserdu |
| Adaptive Biotechnologies Corporation | $16.81 | 2025 | Clonoseq |
| Blue Earth Diagnostics | $16.56 | 2019 | |
| Napo Pharmaceuticals INC | $13.78 | 2025 | Gelclair Concentrated Oral Gel |
| Taiho Oncology, INC. | $13.71 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Gross listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.